Novosanis’ medical device Colli-Pee™ has been approved for sales in the US by FDA

You are here

Wijnegem, Belgium, November 14th 2016: Novosanis, announced today that Colli-Pee™a self-sampling device suited for standardized and guaranteed collection of first-void urine has been listed by the FDA and thus approved for sales in the US.

“The approval of Colli-Pee for commercial use in the US is a major milestone in Novosanis’ history. This opens new opportunities to collaborate with diagnostic companies, suppliers of diagnostic tests, laboratories and hospitals in the US. The Colli-Pee device allows for collection of standardized and guaranteed first-void urine making the sample highly suited for detection of infectious diseases, like Human Papilloma Virus and other sexually transmitted infections, but also biomarkers for detection of early stage cancer.” says Vanessa Vankerckhoven, CEO Novosanis, Belgium.